| Today's Big NewsJun 9, 2023 |
|
Montgomery County, MD, is a thriving innovation hub for the life sciences industry. Be Next and learn how companies are making their mark in the immunology capital next to the nation’s capital. Learn more.
|
|
| By Max Bayer Lilly is aware of and “closely looking into” anecdotes that patients taking GLP-1 drugs seem to have an easier time quitting alcohol or cigarettes—but proving a genuine impact is easier said than done. |
|
|
|
By James Waldron Vertex and CRISPR Therapeutics’ dream of getting the first-ever CRISPR gene editing therapy approved now seems within reach as the candidate aced primary endpoints in a pair of phase 3 trials mere hours after the FDA penciled in a decision date for December. |
By Nick Paul Taylor AstraZeneca is joining Bristol Myers Squibb in the emerging autoimmune cell therapy space, paying Quell Therapeutics $85 million upfront to collaborate on candidates including a “one and done” cure for Type 1 diabetes. |
By Nick Paul Taylor Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy, but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough. |
By Helen Floersh Saracatinib reduced signs of atherosclerosis in mice, rabbits and human plasma and tissue samples. |
By Annalee Armstrong,Gabrielle Masson “Substantially all” of Oncorus’ workforce are heading out the door, including its CEO, COO and CMO. |
By Teresa Carey This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
By Angus Liu David Epstein’s short tenure as Seagen’s CEO will likely end soon with the antibody-drug conjugate specialist’s sale to Pfizer. After a rich career spanning companies of various sizes, Epstein is keeping an open mind about where he might head next. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Andrea Park As Altoida prepares to launch a clinical study that will hopefully make a strong case for FDA clearance for its Alzheimer’s disease-predicting technology, the company has tapped a new chief executive to lead the way. |
By Heather Landi The Centers for Medicare and Medicaid Services aims to advance value-based primary care, especially in rural areas and among underserved populations, with a new pilot project. |
By Zoey Becker Eisai and Biogen's Leqembi may be on its way to a full FDA approval, but first an advisory committee will have its say on the drug. AstraZeneca and Daiichi Sankyo’s Enhertu could break into other tumor types with early data experts call “very compelling.” Samsung Biologics will manufacture biosimilars for Pfizer. Plus more. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Save $500 when you Register before June 19th!
|
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
